Novo Nordisk: positive CHMP opinion for icodec insulin

(CercleFinance.com) - Novo Nordisk announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending marketing authorisation for Awiqli (the brand name of icodec once-weekly basal insulin) for the treatment of diabetes in adults.


The CHMP's positive opinion is based on a Phase 3a trial which showed that icodec once-weekly basal insulin achieved a superior reduction in blood glucose levels, as well as a superior time spent within the recommended blood glucose range, compared to daily basal insulin in people with type 2 diabetes.

We believe that by reducing the number of basal insulin injections from seven to once a week, Awiqli has the potential to make a significant impact and improve treatment for people living with diabetes, Novo Nordisk said.

Novo Nordisk expects to receive final marketing authorisation from the European Commission in about two months.


Copyright (c) 2024 CercleFinance.com. All rights reserved.